NeuroScientific locks in key US FDA meeting
--------------------------------------------------------------------
Source: The Age
Published: 2026-08-13 13:12 UTC+10:00
Section: Business / Companies
Factuality Score: 100
Opinion Category: Neutral
Topics: Health, Australia, Economy & Finance, Financial Markets, Law & Courts, Food & Agriculture, Drugs, Business & Economy, Crime & Justice, Technology
--------------------------------------------------------------------
Snippet:
Perth-based biotech NeuroScientific Biopharmaceuticals has bagged a crucial meeting with the United States Food & Drug Administration (FDA) as it looks to push its patented “StemSmart” technology into a Phase 2 clinical trial in the lucrative US market. The company says the Pre-Investigational New Drug, or Pre-IND, meeting has been scheduled for August 31 and represents a critical regulatory step towards testing its treatment for refractory Crohn’s disease on American patients.
--------------------------------------------------------------------